Latest Articles
Stem Cell Therapy: Revolutionizing Women’s Reproductive Health - BIOENGINEER.ORG
Stem Cell Therapy: Revolutionizing Women’s Reproductive Health BIOENGINEER.ORG
Published: Aug. 30, 2025, 7:33 a.m.
Menstrual blood-derived endometrial stem cells ameliorate neuroinflammation and apoptosis through JAK2/STAT3 signaling pathway in NPC1 mutant cell and mice - Stem Cell Research & Therapy
Menstrual blood-derived endometrial stem cells ameliorate neuroinflammation and apoptosis through JAK2/STAT3 signaling pathway in NPC1 mutant cell and mice Stem Cell Research & Therapy
Published: Aug. 29, 2025, 1:47 a.m.
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. - AInvest
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. AInvest
Published: Aug. 28, 2025, 8:24 a.m.
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork
Published: Aug. 26, 2025, 10:07 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology
Published: Aug. 26, 2025, 6:30 p.m.
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer - Oncology Nursing News
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer Oncology Nursing News
Published: Aug. 26, 2025, 6:04 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced - PharmiWeb.com
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced PharmiWeb.com
Published: Aug. 26, 2025, 4:10 p.m.
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive
Published: Aug. 26, 2025, 3:01 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for - GlobeNewswire
Genmab Receives FDA Breakthrough Therapy Designation for GlobeNewswire
Published: Aug. 26, 2025, 12:06 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Yahoo Finance
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Yahoo Finance
Published: Aug. 26, 2025, noon
Link copied to clipboard!